These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 2158847)
1. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. Murray KJ; England PJ; Hallam TJ; Maguire J; Moores K; Reeves ML; Simpson AW; Rink TJ Br J Pharmacol; 1990 Mar; 99(3):612-6. PubMed ID: 2158847 [TBL] [Abstract][Full Text] [Related]
2. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Simpson AW; Reeves ML; Rink TJ Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518 [TBL] [Abstract][Full Text] [Related]
3. The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function. Murray KJ; Eden RJ; Dolan JS; Grimsditch DC; Stutchbury CA; Patel B; Knowles A; Worby A; Lynham JA; Coates WJ Br J Pharmacol; 1992 Oct; 107(2):463-70. PubMed ID: 1422592 [TBL] [Abstract][Full Text] [Related]
4. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334 [TBL] [Abstract][Full Text] [Related]
5. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets. Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481 [TBL] [Abstract][Full Text] [Related]
7. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Tang KM; Jang EK; Haslam RJ Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608 [TBL] [Abstract][Full Text] [Related]
8. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors. Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501 [TBL] [Abstract][Full Text] [Related]
9. Effects of combination therapy with low-dose aspirin and warfarin on platelet functions after heart valve replacement. Kobune K; Inoue M; Morikawa M; Tsuboi M; Takanami Y; Iwane Y; Kudo T Res Commun Chem Pathol Pharmacol; 1991 Nov; 74(2):153-65. PubMed ID: 1811279 [TBL] [Abstract][Full Text] [Related]
10. DL-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase. Ye J; Zhai L; Zhang S; Zhang Y; Chen L; Hu L; Zhang S; Ding Z Platelets; 2015; 26(8):736-44. PubMed ID: 25734213 [TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets. Yin K; Lai PS; Rodriguez A; Spur BW; Wong PY Prostaglandins; 1995 Sep; 50(3):169-78. PubMed ID: 8750213 [TBL] [Abstract][Full Text] [Related]
12. The cyclic AMP-lowering effect on the stable endoperoxide analog U46619 in human platelets. Bonne C; Martin B; Regnault F Thromb Res; 1980 Dec 1-15; 20(5-6):701-4. PubMed ID: 6262941 [No Abstract] [Full Text] [Related]
13. High concentrations of exogenous arachidonate inhibit calcium mobilization in platelets by stimulation of adenylate cyclase. Kowalska MA; Rao AK; Disa J Biochem J; 1988 Jul; 253(1):255-62. PubMed ID: 2458717 [TBL] [Abstract][Full Text] [Related]
14. Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate. Hourani SM; Hall DA; Nieman CJ Br J Pharmacol; 1992 Feb; 105(2):453-7. PubMed ID: 1559134 [TBL] [Abstract][Full Text] [Related]
15. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro. Azuma H; Takashima Y; Ishikawa M; Yamakado T Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194 [TBL] [Abstract][Full Text] [Related]
16. Augmentation of U46619 induced human platelet aggregation by aspirin. Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053 [TBL] [Abstract][Full Text] [Related]
17. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative. Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809 [TBL] [Abstract][Full Text] [Related]